Acuta Capital Partners’s AtriCure ATRC Stock Holding History

Acuta Capital Partners’s Portfolio ATRC Stock Details ATRC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-66,186	Closed	-$1.05M	–	55
2016 Q3	$1.05M	Sell	66,186 -46,737	-41%	-$718K	0.39%	44
2016 Q2	$1.6M	Buy	+112,923	New	+$1.72M	0.77%	36

Other funds holding ATRC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

HEC

Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

PCM

Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Acuta Capital Partners's ATRC Position: Q4 2016 in Review

Acuta Capital Partners sold out of AtriCure (ATRC) in Q4 2016, closing a stake of 66,186 shares — an estimated $1.05M sold.

Acuta Capital Partners first reported a position in ATRC in Q2 2016 and held it in 2 quarters. The position peaked at $1.6M in Q2 2016. 100 funds tracked by Wall St. Rank hold ATRC as of Q4 2016.

Acuta Capital Partners reported no remaining AtriCure position as of Q4 2016 after selling out during the quarter.
Acuta Capital Partners sold 66,186 AtriCure shares in Q4 2016, an estimated $1.05M.
Acuta Capital Partners first reported a position in AtriCure in Q2 2016 and held it in 2 quarters.
Acuta Capital Partners's AtriCure position peaked at $1.6M in Q2 2016.
100 funds tracked by Wall St. Rank held AtriCure as of Q4 2016.

Based on Acuta Capital Partners's 13F filing for Q4 2016, filed 13 Feb 2017.